The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | 74,681 | 58,839 | - | - |
| Salaries | 303,478 | 242,795 | - | - |
| Consumables | 102,905 | 77,543 | - | - |
| Platform | 49,209 | 15,876 | - | - |
| Discovery | 68,193 | 30,480 | - | - |
| Clinical development | 46,383 | 43,713 | - | - |
| Depreciation and amortization | 83,701 | 36,494 | - | - |
| Other segment items | 68,944 | 90,942 | - | - |
| Loss from operations | -648,132 | -479,004 | - | - |
| Other non-operating income, net | 3,237 | 14,216 | - | - |
| Income tax benefit | -136 | -1,127 | - | - |
| Net loss | -644,759 | -463,661 | -328,066 | -239,476 |
| Depreciation and amortization | 83,701 | 36,494 | 24,402 | 11,756 |
| Stock-based compensation | 111,223 | 81,688 | 53,503 | 27,909 |
| Asset impairment | 5,956 | 108 | 1,188 | 2,806 |
| Lease expense | 22,249 | 16,616 | 8,063 | 7,730 |
| Loss on disposal of a business | -4,502 | - | - | - |
| Loss on debt extinguishment | - | - | 0 | 0 |
| Acquired ipr&d | 22,082 | - | - | - |
| Other, net | -9,550 | -7,582 | -3,387 | -830 |
| Other receivables and assets | -32,939 | 6,071 | 7,756 | 2 |
| Prepaid data assets | -49,859 | - | - | - |
| Unearned revenue | -36,771 | -28,038 | -41,076 | 110,320 |
| Accounts payable | -2,616 | 6,435 | -987 | 1,767 |
| Accrued development expense | -2,328 | -264 | 2,705 | 522 |
| Accrued expenses and other current liabilities | -7,407 | 5,519 | 6,719 | -576 |
| Operating lease liabilities | - | - | -9,862 | -7,110 |
| Lease liabilities | -19,988 | -15,582 | - | - |
| Net cash used in operating activities | -371,808 | -359,174 | -287,780 | -83,524 |
| Net cash acquired in the acquisition of a business | 0 | -277,104 | -1,844 | 0 |
| Purchases of property and equipment | 6,469 | 13,695 | 11,955 | 37,059 |
| Purchases of intangible assets | 2,158 | 3,350 | 597 | 300 |
| Purchases of investments | - | - | 0 | 0 |
| Decrease in cash related to disposal of a business | -4,438 | - | - | - |
| Sales and maturities of investments | - | - | 480 | 230,608 |
| Purchases of investments | 3,806 | - | - | - |
| Proceeds from note receivable | - | - | - | 0 |
| Sales and maturities of investments | 0 | 0 | - | - |
| Net cash provided by (used in) investing activities | -16,871 | 260,059 | -10,228 | 193,249 |
| Proceeds from issuance of common shares, net of issuance costs | 528,864 | 300,417 | 128,093 | 143,711 |
| Proceeds from initial public offering of common stock, net of issuance costs | - | - | - | 0 |
| Proceeds from sale of preferred stock, net of issuance costs | - | - | - | 0 |
| Proceeds from equity incentive plans | 4,093 | 8,143 | 12,806 | 10,724 |
| Repayment of long-term debt | - | - | 766 | 90 |
| Repayment of long-term debt and finance lease liabilities | 8,425 | 4,440 | - | - |
| Proceeds from convertible notes | - | - | - | 0 |
| Purchase of an intangible asset | 3,000 | - | - | - |
| Net cash provided by financing activities | 521,532 | 304,120 | 140,133 | 154,345 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 18,044 | -3,406 | 188 | -307 |
| Net change in cash, cash equivalents and restricted cash | 150,897 | 201,599 | -157,687 | 263,763 |
| Cash, cash equivalents and restricted cash, beginning of period | 603,024 | 401,425 | 559,112 | 295,349 |
| Cash, cash equivalents and restricted cash, end of period | 753,921 | 603,024 | 401,425 | 559,112 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)